| Year |
Citation |
Score |
| 2024 |
Galetin A, Brouwer KLR, Tweedie D, Yoshida K, Sjöstedt N, Aleksunes L, Chu X, Evers R, Hafey MJ, Lai Y, Matsson P, Riselli A, Shen H, Sparreboom A, Varma MVS, ... ... Zamek-Gliszczynski MJ, et al. Membrane transporters in drug development and as determinants of precision medicine. Nature Reviews. Drug Discovery. PMID 38267543 DOI: 10.1038/s41573-023-00877-1 |
0.354 |
|
| 2023 |
Barth A, Perry CR, Shabbir S, Zamek-Gliszczynski MJ, Thomas S, Dumont EF, Brimhall DB, Nguyen D, Srinivasan M, Swift B. Clinical Assessment of Gepotidacin (GSK2140944) as a Victim and Perpetrator of Drug-Drug Interactions via CYP3A Metabolism and Transporters. Clinical and Translational Science. PMID 36642822 DOI: 10.1111/cts.13477 |
0.353 |
|
| 2022 |
Taskar KS, Yang X, Neuhoff S, Patel M, Yoshida K, Paine MF, Brouwer KLR, Chu X, Sugiyama Y, Cook J, Polli JW, Hanna I, Lai Y, Zamek-Gliszczynski M, Itc T. Clinical relevance of hepatic and renal P-gp/BCRP inhibition of drugs: An International Transporter Consortium perspective. Clinical Pharmacology and Therapeutics. PMID 35612761 DOI: 10.1002/cpt.2670 |
0.332 |
|
| 2022 |
Zamek-Gliszczynski MJ, Sangha V, Shen H, Feng B, Wittwer MB, Varma MVS, Liang X, Sugiyama Y, Zhang L, Bendayan R. Transporters in drug development: International transporter consortium update on emerging transporters of clinical importance. Clinical Pharmacology and Therapeutics. PMID 35561119 DOI: 10.1002/cpt.2644 |
0.375 |
|
| 2020 |
Unger MS, Schumacher L, Enzlein T, Weigt D, Zamek-Gliszczynski MJ, Schwab M, Nies AT, Drewes G, Schulz S, Reinhard FBM, Hopf C. Direct Automated MALDI Mass Spectrometry Analysis of Cellular Transporter Function: Inhibition of OATP2B1 Uptake by 294 Drugs. Analytical Chemistry. 92: 11851-11859. PMID 32867487 DOI: 10.1021/Acs.Analchem.0C02186 |
0.453 |
|
| 2020 |
Zamek-Gliszczynski MJ, Patel M, Yang X, Lutz JD, Chu X, Brouwer KLR, Lai Y, Lee CA, Neuhoff S, Paine MF, Sugiyama Y, Taskar KS, Galetin A. Intestinal P-gp and Putative Hepatic OATP1B Induction: ITC Perspective on Drug Development Implications. Clinical Pharmacology and Therapeutics. PMID 32460379 DOI: 10.1002/Cpt.1916 |
0.37 |
|
| 2019 |
Unger MS, Mudunuru J, Schwab M, Hopf C, Drewes G, Nies AT, Zamek-Gliszczynski MJ, Reinhard F. Clinically-relevant OATP2B1 inhibitors in marketed drug space. Molecular Pharmaceutics. PMID 31834804 DOI: 10.1021/Acs.Molpharmaceut.9B00897.S001 |
0.398 |
|
| 2019 |
Patel M, Eberl HC, Wolf A, Pierre E, Polli JW, Zamek-Gliszczynski MJ. Mechanistic basis of cabotegravir-glucuronide disposition in humans. The Journal of Pharmacology and Experimental Therapeutics. PMID 31175220 DOI: 10.1124/Jpet.119.258384 |
0.572 |
|
| 2019 |
Zamek-Gliszczynski MJ, Zhang X, Mudunuru J, Du Y, Chen JL, Taskar KS, Huang J, Huang Y, Romach EH. Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 31167838 DOI: 10.1124/Dmd.119.087635 |
0.416 |
|
| 2018 |
Zamek-Gliszczynski MJ, Taub ME, Chothe PP, Chu X, Giacomini KM, Kim RB, Ray AS, Stocker SL, Unadkat JD, Wittwer MB, Xia C, Yee SW, Zhang L, Zhang Y. Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clinical Pharmacology and Therapeutics. PMID 30091177 DOI: 10.1002/Cpt.1112 |
0.462 |
|
| 2018 |
Patel M, Johnson M, Sychterz CJ, Lewis GJ, Watson C, Ellens H, Polli JW, Zamek-Gliszczynski MJ. Hepatobiliary disposition of atovaquone: A case of mechanistically unusual biliary clearance. The Journal of Pharmacology and Experimental Therapeutics. PMID 29653960 DOI: 10.1124/Jpet.117.247254 |
0.574 |
|
| 2017 |
Zamek-Gliszczynski MJ, Giacomini KM, Zhang L. Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions. Clinical Pharmacology and Therapeutics. PMID 29193038 DOI: 10.1002/Cpt.941 |
0.321 |
|
| 2016 |
Patel M, Taskar KS, Zamek-Gliszczynski MJ. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. Journal of Clinical Pharmacology. 56: S23-S39. PMID 27385177 DOI: 10.1002/Jcph.671 |
0.415 |
|
| 2016 |
Scheer N, Chu X, Salphati L, Zamek-Gliszczynski MJ. Knockout and humanised animal models to study membrane transporters in drug development Rsc Drug Discovery Series. 2016: 298-332. DOI: 10.1039/9781782623793-00298 |
0.397 |
|
| 2015 |
Xie F, Ke AB, Bowers GD, Zamek-Gliszczynski MJ. Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. The Journal of Pharmacology and Experimental Therapeutics. 354: 225-9. PMID 26062557 DOI: 10.1124/Jpet.115.225698 |
0.307 |
|
| 2015 |
Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 490-509. PMID 25587128 DOI: 10.1124/Dmd.114.062174 |
0.401 |
|
| 2014 |
Lee CA, Kalvass JC, Galetin A, Zamek-Gliszczynski MJ. ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays. Clinical Pharmacology and Therapeutics. 96: 298-301. PMID 25141954 DOI: 10.1038/clpt.2014.94 |
0.331 |
|
| 2014 |
Higgins JW, Ke AB, Zamek-Gliszczynski MJ. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1780-4. PMID 25106415 DOI: 10.1124/Dmd.114.058784 |
0.582 |
|
| 2014 |
Zamek-Gliszczynski MJ, Chu X, Polli JW, Paine MF, Galetin A. Understanding the transport properties of metabolites: case studies and considerations for drug development. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 650-64. PMID 24346835 DOI: 10.1124/Dmd.113.055558 |
0.459 |
|
| 2014 |
Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK, Smith PC, Zamek-Gliszczynski MJ. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 182-92. PMID 24194513 DOI: 10.1124/Dmd.113.054783 |
0.487 |
|
| 2013 |
Zamek-Gliszczynski MJ, Bao JQ, Day JS, Higgins JW. Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1967-71. PMID 24009308 DOI: 10.1124/Dmd.113.053025 |
0.421 |
|
| 2013 |
Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, Pang KS, Korzekwa K, Swaan PW, Taub ME, Zhao P, et al. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clinical Pharmacology and Therapeutics. 94: 64-79. PMID 23588311 DOI: 10.1038/Clpt.2013.45 |
0.322 |
|
| 2013 |
Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, Zamek-Gliszczynski MJ. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clinical Pharmacology and Therapeutics. 94: 80-94. PMID 23588303 DOI: 10.1038/Clpt.2013.34 |
0.404 |
|
| 2013 |
Zamek-Gliszczynski MJ, Goldstein KM, Paulman A, Baker TK, Ryan TP. Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1174-8. PMID 23569176 DOI: 10.1124/Dmd.113.051409 |
0.564 |
|
| 2013 |
Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, Kulanthaivel P, Jackson KA, Chow KH, McCann DJ, Hu H, Anderson S, Furr NA, Barbuch RJ, Cassidy KC. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 714-26. PMID 23305709 DOI: 10.1124/Dmd.112.048488 |
0.501 |
|
| 2012 |
Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, Giacomini KM, Hillgren KM. Highlights from the international transporter consortium second workshop Clinical Pharmacology and Therapeutics. 92: 553-556. PMID 23085880 DOI: 10.1038/Clpt.2012.126 |
0.732 |
|
| 2012 |
Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1825-33. PMID 22711747 DOI: 10.1124/Dmd.112.046508 |
0.514 |
|
| 2012 |
Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1170-7. PMID 22407892 DOI: 10.1124/Dmd.112.044875 |
0.425 |
|
| 2011 |
Zamek-Gliszczynski MJ, Day JS, Hillgren KM, Phillips DL. Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1794-800. PMID 21708882 DOI: 10.1124/Dmd.111.040162 |
0.549 |
|
| 2011 |
Zamek-Gliszczynski MJ, Ruterbories KJ, Ajamie RT, Wickremsinhe ER, Pothuri L, Rao MV, Basavanakatti VN, Pinjari J, Ramanathan VK, Chaudhary AK. Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. Journal of Pharmaceutical Sciences. 100: 2498-507. PMID 21213309 DOI: 10.1002/Jps.22452 |
0.328 |
|
| 2010 |
Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, ... ... Zamek-Gliszczynski MJ, et al. Membrane transporters in drug development. Nature Reviews. Drug Discovery. 9: 215-36. PMID 20190787 DOI: 10.1038/Nrd3028 |
0.762 |
|
| 2009 |
Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, Brouwer KL. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 386-90. PMID 19022942 DOI: 10.1124/Dmd.108.023648 |
0.648 |
|
| 2008 |
Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Brouwer KL. Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 2156-8. PMID 18719241 DOI: 10.1124/Dmd.108.022053 |
0.813 |
|
| 2008 |
Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, Brouwer KL. Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 911-5. PMID 18276836 DOI: 10.1124/Dmd.107.019273 |
0.704 |
|
| 2008 |
Lee JK, Leslie EM, Zamek-Gliszczynski MJ, Brouwer KL. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicology and Applied Pharmacology. 228: 17-23. PMID 18191164 DOI: 10.1016/J.Taap.2007.11.020 |
0.706 |
|
| 2008 |
Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, Raub TJ, Brouwer KL. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 61-4. PMID 17913796 DOI: 10.1124/Dmd.107.017319 |
0.732 |
|
| 2007 |
Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, Brouwer KL. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrobial Agents and Chemotherapy. 51: 3230-4. PMID 17576841 DOI: 10.1128/Aac.00082-07 |
0.68 |
|
| 2006 |
Zamek-Gliszczynski MJ, Nezasa K, Tian X, Bridges AS, Lee K, Belinsky MG, Kruh GD, Brouwer KL. Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. The Journal of Pharmacology and Experimental Therapeutics. 319: 1485-91. PMID 16988054 DOI: 10.1124/Jpet.106.110106 |
0.718 |
|
| 2006 |
Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, Brouwer KL. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Molecular Pharmacology. 70: 2127-33. PMID 16959944 DOI: 10.1124/Mol.106.026955 |
0.711 |
|
| 2006 |
Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KL. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. The Journal of Pharmacology and Experimental Therapeutics. 319: 459-67. PMID 16857726 DOI: 10.1124/Jpet.106.101840 |
0.821 |
|
| 2006 |
Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KL. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 27: 447-86. PMID 16472997 DOI: 10.1016/J.Ejps.2005.12.007 |
0.783 |
|
| 2006 |
Nezasa K, Tian X, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KL. Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 718-23. PMID 16434545 DOI: 10.1124/Dmd.105.007922 |
0.649 |
|
| 2005 |
Tian X, Zhang P, Zamek-Gliszczynski MJ, Brouwer KL. Knocking down transport: applications of RNA interference in the study of drug transport proteins. Drug Metabolism Reviews. 37: 705-23. PMID 16393889 DOI: 10.1080/03602530500364098 |
0.567 |
|
| 2005 |
Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE, Webster LO, Bridges AS, Kalvass JC, Brouwer KL. Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 1158-65. PMID 15860656 DOI: 10.1124/Dmd.104.002188 |
0.812 |
|
| 2005 |
Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 287-93. PMID 15528320 DOI: 10.1124/Dmd.104.001420 |
0.808 |
|
| 2005 |
Kemp DC, Zamek-Gliszczynski MJ, Brouwer KL. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicological Sciences : An Official Journal of the Society of Toxicology. 83: 207-14. PMID 15509663 DOI: 10.1093/Toxsci/Kfi020 |
0.705 |
|
| 2004 |
Tian X, Zamek-Gliszczynski MJ, Zhang P, Brouwer KL. Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Molecular Pharmacology. 66: 1004-10. PMID 15385645 DOI: 10.1124/mol.66.4. |
0.644 |
|
| 2004 |
Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. The Journal of Pharmacology and Experimental Therapeutics. 311: 1203-10. PMID 15302892 DOI: 10.1124/Jpet.104.070201 |
0.807 |
|
| 2003 |
Patel NJ, Zamek-Gliszczynski MJ, Zhang P, Han YH, Jansen PL, Meier PJ, Stieger B, Brouwer KL. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Molecular Pharmacology. 64: 154-9. PMID 12815171 DOI: 10.1124/Mol.64.1.154 |
0.702 |
|
| 2003 |
Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL. Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. The Journal of Pharmacology and Experimental Therapeutics. 304: 801-9. PMID 12538836 DOI: 10.1124/Jpet.102.044107 |
0.812 |
|
| Show low-probability matches. |